Enanta Pharmaceuticals, Inc. Company Profile & Data: stocks, market cap, financials, digital and more

                        
Company
Enanta Pharmaceuticals, Inc.Headquarters: Watertown, 
                        MA, United States
                    
Employees: 155
CEO: Dr. Jay R. Luly

                                    NASDAQ: ENTA
                                
                                            -3.62%
                                            
Market Cap$117.4 Million

                        USD as of Jan. 1, 2025
                    
                            Market Cap History

Enanta Pharmaceuticals, Inc. Categories

United States Healthcare Biotechnology
United States Healthcare United States Biotechnology

Enanta Pharmaceuticals, Inc. market capitalization over time

Evolution of Enanta Pharmaceuticals, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Enanta Pharmaceuticals, Inc.

Top Competitors by Market Capitalization

Industry: Biotechnology

Company	Market Cap (USD)
Novo Nordisk	$622.07 B
Vertex Pharmaceuticals Incorporated	$113.24 B
CSL Limited	$95.75 B
Regeneron Pharmaceuticals, Inc.	$76.33 B
Marinomed Biotech AG	$56.13 B

Sector:

Company	Market Cap (USD)
Lilly	$689.42 B
Novo Nordisk	$622.07 B
UnitedHealth Group	$487.54 B
Johnson & Johnson	$353.05 B
AbbVie	$301.60 B

Detailed Description

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Top 1-year algo backtest: +327.04%

$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Financials

Last Financial Reports Date	Dec. 31, 2023
Revenue TTM	$73.6 M
EBITDA	$-139,578,000
Gross Profit TTM	$0
Profit Margin	-187.77%
Operating Margin	-193.78%
Quarterly Revenue Growth	-23.70%